Archives

  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Quercetin Modulates Myocardial Fibrosis via miR-223-3p/FOXO3

    2026-05-25

    Quercetin Modulates Myocardial Fibrosis via miR-223-3p/FOXO3-Autophagy Axis

    Study Background and Research Question

    Myocardial fibrosis (MF) is a central pathological feature underlying structural remodeling in atrial fibrillation (AF), contributing to both the onset and progression of this highly prevalent arrhythmia. As the aging population grows, the clinical burden of AF is expected to rise, with epidemiological data indicating that up to 7.1% of individuals over 85 experience AF, and associated mortality is elevated 1.5–2 fold compared to those without AF (reference study). The molecular mechanisms that drive MF and its link to AF, particularly the roles of autophagy and microRNA signaling, remain incompletely understood. Flavonoids such as quercetin have shown cardioprotective effects, but the precise pathways involved in the attenuation of cardiac fibrosis had yet to be clarified prior to this work.

    Key Innovation from the Reference Study

    The study by Hua et al. offers mechanistic insight into how quercetin exerts an anti-fibrotic effect in the setting of isoprenaline-induced MF by modulating the miR-223-3p/FOXO3 axis and subsequently promoting autophagic activity (Hua et al., 2021). This work is distinguished by its integration of human tissue analysis, rodent models, and in vitro cellular assays to dissect the interplay between noncoding RNA, transcription factor regulation, and autophagy in cardiac pathology. By demonstrating that quercetin downregulates miR-223-3p and upregulates FOXO3, thereby activating autophagy and suppressing fibrosis, the study identifies a previously uncharacterized regulatory loop with therapeutic potential.

    Methods and Experimental Design Insights

    The investigators employed a multilayered approach:
    • Clinical tissue analysis: Cardiac samples were obtained from AF patients and compared to those with sinus rhythm, focusing on expression levels of miR-223-3p, FOXO3, and autophagy-related proteins.
    • In vivo rodent model: Aged rats were treated with isoprenaline to induce MF, with or without quercetin intervention. Cardiac fibrosis extent, gene expression, and autophagy markers were assessed post-treatment.
    • In vitro studies: Human 293T cell lines were used to further delineate the molecular mechanisms of miR-223-3p and FOXO3 in the autophagic response to quercetin.
    • Molecular assays: Quantitative PCR and western blotting were used to assess transcript and protein levels of miR-223-3p, FOXO3, ATG7, p62/SQSTM1, and LC3B isoforms, linking these to autophagic flux and fibrotic outcomes.

    Protocol Parameters

    • Quercetin administration: In vivo, quercetin was administered to rats following isoprenaline-induced cardiac injury; precise dosing and timing were optimized for maximal anti-fibrotic effect as described in the study.
    • Tissue collection: Cardiac tissues were harvested post-intervention for histological analysis and molecular profiling of autophagy and fibrosis markers.
    • Gene expression measurement: RNA was extracted for miRNA and mRNA quantification, while protein lysates were probed for autophagy pathway components.
    • Cell line assays: 293T cells were transfected or treated with specific modulators to dissect miR-223-3p/FOXO3 pathway dynamics in vitro.
    These parameters offer a reproducible model for mechanistic investigation of anti-fibrotic interventions in both animal and cellular systems.

    Core Findings and Why They Matter

    The data revealed that both clinical AF tissues and isoprenaline-treated rat myocardium exhibited elevated miR-223-3p expression, concurrent with reduced FOXO3 levels and suppressed autophagy (as indicated by lower ATG7, altered LC3B-II/LC3B-I ratio, and increased p62/SQSTM1). Quercetin administration reversed these trends: miR-223-3p was downregulated, FOXO3 was upregulated, autophagic flux increased, and myocardial fibrosis was significantly attenuated (Hua et al., 2021). These findings indicate a pathologically relevant regulatory axis wherein miR-223-3p suppresses FOXO3, dampening autophagy and facilitating fibrosis; quercetin disrupts this axis, offering molecular targets for future anti-fibrotic therapies.

    Comparison with Existing Internal Articles

    Recent resources on advanced in vitro cell proliferation and viability assays, such as those utilizing MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide), provide practical context for metabolic activity measurement in similar mechanistic studies. For example, the article "MTT Tetrazolium Salt for Cell Viability Assays: Advanced..." underscores best practices for using MTT as a colorimetric cell viability assay reagent, relevant when assessing metabolic changes in fibrosis models. Likewise, "MTT: Optimizing 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium Bromide Cell Assays" details troubleshooting and protocol refinement, which can inform experimental workflows for measuring cell proliferation and viability during interventions such as quercetin treatment. While the reference study did not directly employ MTT, integrating validated metabolic activity measurement tools strengthens reproducibility in similar research contexts. The internal guides highlight how the choice of in vitro cell proliferation assay reagent—such as a high-purity tetrazolium salt—supports robust quantification of treatment effects on cell health and function.

    Limitations and Transferability

    Several limitations are noted. First, while the study demonstrates quercetin’s effects in both rat and human-derived samples, translation to clinical therapy for AF requires further validation in large cohorts and diverse populations. The reliance on isoprenaline-induced fibrosis as a model system, while established, may not capture all facets of human cardiac remodeling. Additionally, while autophagy and the miR-223-3p/FOXO3 axis are clearly implicated, the broader transcriptomic and proteomic landscape influencing fibrosis was not comprehensively mapped. Future studies should address potential off-target effects of quercetin and explore the therapeutic window for intervention.

    Research Support Resources

    For investigators seeking to model cardiac fibrosis or assess cellular responses to candidate therapeutics, adoption of robust in vitro metabolic activity measurement is essential. Researchers can utilize MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) (SKU B7777) from APExBIO as a reliable in vitro cell viability and proliferation assay reagent. MTT’s proven utility as a NADH-dependent oxidoreductase substrate supports sensitive detection of metabolic changes during fibrosis, autophagy, and cardioprotective intervention studies. For further protocol guidance and troubleshooting, internal resources such as "Translating Mechanism to Impact: Strategic Insights for MTT Use" are available to streamline assay optimization and data interpretation.